Items tagged with Scientific research

Understanding TB from the bacterium’s point of view (post)

At Tufts University School of Medicine, Shumin Tan is investigating the human-microbe relationship to advance not just an understanding of tuberculosis, but any infection.

Proteomics reveals potential targets for drug-resistant TB (post)

TOPLINE:

Down-regulation of plasma exosome-derived apolipoproteins APOA1, APOB, and APOC1 indicates DR-TB status and lipid metabolism regulation in pathogenesis. 

TB therapy: Smallest particles will deliver the drug to the lungs in future (post)

KIT and Research Center Borstel present nanoparticles with a high antibiotic concentration for inhalation – nanocarriers of antibiotics can reduce resistances and enhance compatibility

Molecular insights may inform new treatments for drug-resistant TB (post)

In the face of growing antibiotic resistance among bacterial infections, scientists at The Hospital for Sick Children (SickKids) have delved into the molecular science behind treatment-resistant tuberculosis.

Fresh insights into how glucose drives TB vaccine responses offer hope for improved efficacy (post)

BCG is a live bacterial vaccine, of limited effectiveness for tuberculosis, but it's the only one we've got. However, scientists in the TB Immunology group at Trinity College Dublin and St. James's Hospital have provided fresh insights into the behaviour of a crucial cell in vaccine mechanisms, which may offer a fresh target for scientists seeking to improve vaccine efficacy.

Researchers find a chink in the armor of TB pathogen (post)

Mycobacterium tuberculosis (Mtb) is the pathogen that causes tuberculosis (TB), the world's deadliest infectious disease. Mtb is so successful and harmful because it can adapt to different conditions inside our bodies, allowing it to evade treatment.

NIH awards SMU chemistry professor and his team $3.5M to refine and test new TB treatments (post)

DALLAS (SMU), September 19, 2023 – Southern Methodist University (SMU) chemistry professor John Buynak and his team have received a $3.5 million, 5-year grant from the National Institutes of Health to design and synthesize new antibiotics to fight some of the deadliest and most clinically challenging infections of the 21st century – drug resistant strains of bacteria that cause tuberculosis and leprosy.

Study finds potential way to tweak immune system to help it fight TB (post)

Tuberculosis is old—ancient even. The infectious bacterial disease that plagued Old Testament Israelites and took down pharaohs was eventually stunted by vaccinations, antibiotics, and public health measures like isolation—but it hasn’t been cured yet. More than a million people around the world still die from TB every year.

AN2 Therapeutics signs grant agreement to discover novel, boron based therapies for TB and malaria (post)

MENLO PARK, Calif., Sep. 26, 2023 -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that it has received a research grant from the Bill & Melinda Gates Foundation to discover novel, boron containing small molecules for the treatment of tuberculosis and malaria. Funding from the Gates Foundation will support the discovery of novel inhibitors of aminoacyl-tRNA synthetases using AN2’s proprietary boron chemistry platform. AN2’s boron chemistry has the potential to address biological targets for tuberculosis and malaria that build on the scientific expertise of several AN2 scientists that were involved in discovering novel leucyl-tRNA synthetase inhibitors including epetraborole, tavaborole, as well as ganfeborole, which is currently in development for tuberculosis. AN2’s boron chemistry platform has demonstrated success against leucyl- tRNA synthetase, a target that has proven difficult to inhibit using traditional medicinal chemistry approaches.

Why TB bacteria form long chains (post)

A researcher team from Ecole Polytechnique Federal de Lausanne led by Dr. Vivek Thacker now group leader at the Department of Infectious Diseases at Heidelberg University Hospital have studied why tuberculosis bacteria form long strands and how this affects their infectivity. Their findings could lead to new therapies and have been published in the journal Cell.